AllDocs -> cancers

POSITION STATEMENT TESTICULAR CANCER Overview The testicles are two egg-shaped gland s found in men. They produce semen and sex hormones. Testicular cancer is one of the more rare forms of cancer with an estimated incidence of approximately 6 in every 100,000 men. 1 Young men are more commonly affected by testicular cancer , with about half of the new diagnoses being made in men under the age of 33 years. 2 There are two different types of testicular cancer , non-seminoma, a cancer of the mature germ cells affecting mostly the 15-35 male year old age group and seminoma, cancer formed from immature germ cells, which generally affects the 25-55 male age group. The outlook for men diagnosed with testicular cancer has improved dramatically since the 1970s when chemotherapy was introduced to treat the disease. Five-year relative survival ...

Indian Journal of Pediatrics, Volume 72—August, 2005 693 Clinical Brief Correspondence and Reprint requests : Dr. Ashish Suri, 34, Ganga Apartments, Alaknanda, New Delhi-110019, Fax : 011-26862663 Intraventricular Rhabdoid Tumor Faiz Uddin Ahmad, Ashish Suri, Ashok Kumar Mahapatra, Veer Singh Mehta, Ajay Garg 1 , M.C. Sharma 2 and Epari Sridhar 2 Departments of Neurosurgery, 1 Neuroradiology and 2 Neuropathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India Abstract. Malignant rhabdoid tumor (MRT) most commonly occurs in kidney. In the central nervous system, cerebellum is the most common site of occurrence. CNS rhabdoid tumors typically occur in small children, do not respond favorably to treatment and are usually fatal within ...

Italian September 2005 [OTH-7630] 1 / 2 Il cancro del seno Breast Cancer Una diagnosi precoce può salvarti la vita Ciò che può fare ogni donna per scoprire un cancro al seno allo stadio iniziale Una diagnosi precoce del cancro del seno offre le migliori possibilità di curarlo e potrebbe salvarti la vita. Ecco quel che può fare ogni donna per scoprire il cancro del seno nella fase iniziale. Ricordati che può capitare anche a te Qualunque sia la tua età, controlla regolarmente il tuo seno, osservandolo bene e palpandolo. Non c’è bisogno di conoscere metodi speciali, uno vale quanto l’altro, anche se certe donne preferiscono attenersi sempre allo stesso sistema. Se noti qualcosa di insolito, vai a farti vedere da un medico, senza indugio. Ricordati che può capitare anche a te, anche se ti sottoponi regolarmente alla mammografia. Sottoponiti a mammografie ...

Evidence-based Series #12-4: Section 1 The Role of Neurokinin-1 Receptor Antagonists in the Prevention of Emesis due to High-dose Cisplatin: A Clinical Practice Guideline D. Warr, T. Oliver, and members of the Systemic Treatment Disease Site Group A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Developed by the Systemic Treatment Disease Site Group Report Date: April 5, 2005 Question What is the role of neurokinin-1 (NK-1) receptor antagonists in the prevention of nausea and vomiting due to chemotherapy with high-dose cisplatin? Outcomes of interest include emesis, nausea, adverse events related to treatment and quality of life. Target Population These recommendations apply to adult cancer patients scheduled to receive high single doses of cisplatin delivered alone or as part of a combined chemotherapy regimen. Recommendations ...

Primary Treatment for Locally Advanced Cervical Cancer : Concurrent Platinum-based Chemotherapy and Radiation Practice Guideline Report #4-5 H. Lukka, H. Hirte, A. Fyles, G. Thomas, M. Fung Kee Fung, M. Johnston, and members of the Gynecology Cancer Disease Site Group ORIGINAL GUIDELINE: August 26, 2002 MOST RECENT LITERATURE SEARCH: June 2004 NEW EVIDENCE ADDED TO GUIDELINE REPORT: June 2004 New evidence found by update searches since completion of the original guideline is consistent with the original recommendations. SUMMARY Guideline Question For women with cervical cancer in whom radiotherapy is considered appropriate, does the addition of concurrent platinum-based chemotherapy improve survival and quality of life with acceptable toxicity? Target Population These recommendations apply to women with cervical cancer for whom primary treatment ...

Summary of Recommendation • The U.S. Preventive Services Task Force (USPSTF) concludes that the evidence is insufficient to recommend for or against routine screening for prostate cancer using prostate specific antigen (PSA) testing or digital rectal examination (DRE). I recommendation. The USPSTF found good evidence that PSA screening can detect early-stage prostate cancer but mixed and inconclusive evidence that early detection improves health outcomes. Screening is associated with important harms, including frequent false- positive results and unnecessary anxiety, biopsies, and potential complications of treatment of some cancers that may never have affected a patient’s health. The USPSTF concludes that evidence is insufficient to determine whether the benefits outweigh the harms for a screened population. Clinical Considerations ...

XII 149 National Cancer Institute SEER Pediatric Monograph CANCER AMONG INFANTS HIGHLIGHTS Incidence ? The age of peak cancer incidence among children occurred during the first year of life (Figure XII.1). ? Malignancies of infancy represented 10% of all cancer that was diagnosed among children younger than 15 years of age. The average annual incidence rate of all infant cancer combined was 233 per million infants, which was 12% higher than the age (2 years) with the next highest incidence. ? The rate among females (234 per million infants) was essentially the same as that in males (232 per million infants). This is notable because infancy was the only age among children younger than 15 years of age in which female rates were not lower than male rates. ? Neuroblastoma comprised 28% of infant cancer cases and was the most ...

ICCC VI 79 RENAL TUMORS 79 National Cancer Institute 79 National Cancer Institute SEER Pediatric Monograph 79 National Cancer Institute SEER Pediatric Monograph Leslie Bernstein, Martha Linet, Malcolm A. Smith, Andrew F. Olshan HIGHLIGHTS Incidence ? Malignancies of the kidney (renal cancers ) represented 6.3% of cancer diagnoses among children younger than 15 years of age (incidence 7.9 per million) (Table VI.2) and 4.4% of cancer diagnoses for children and adolescents younger than 20 years of age (incidence of 6.2 per million). ? In the US approximately 550 children and adolescents younger than 20 years of age are diagnosed with renal tumors each year, of which approximately 500 are Wilms’ tumor . ? Wilms’ tumor was by far the most common form of renal cancer in children ...

ICCC VIII MALIGNANT BONE TUMORS 99 National Cancer Institute SEER Pediatric Monograph HIGHLIGHTS Incidence ? Malignancies of the bone, with an average annual incidence rate of 8.7 per million children younger than 20 years of age, comprised about 6% of childhood cancer reported by SEER areas from 1975-95. ? In the US, 650-700 children and adolescents younger than 20 years of age are diagnosed with bone tumors each year of which approximately 400 are osteosar- coma and 200 are Ewing’s sarcoma. ? The two types of malignant bone cancer that predominated in children were os- teosarcomas and Ewing’s sarcomas, about 56% and 34% of the malignant bone tumors , respectively. ? Osteosarcomas derive from primitive bone-forming mesenchymal stem cells and most often occur near the metaphyseal portions of the long bones. The Ewing’s ...

ICCC VII HEPATIC TUMORS Marc Bulterys, Marc T. Goodman, Malcolm A. Smith, Jonathan D. Buckley 91 National Cancer Institute SEER Pediatric Monograph HIGHLIGHTS Incidence ? Primary neoplasms of the liver are rare in children, comprising only 1.1% of malig- nancies for children younger than 20 years of age. In the US, 100-150 children are diagnosed with liver cancer each year. ? Primary liver cancer is subdivided into the following histologic subtypes: hepatoblastoma comprises over two-thirds of the malignant tumors of the liver in children and adolescents (79% <15 years of age; 66% <20 years of age) and hepatocellular carcinoma accounts for most of the remaining cases. Hepatoblastoma occurs primarily in children younger than 5 years of age while hepatocellular carcinoma occurs primarily after 10 years of age (Figure VII.2). ...

175 National Cancer Institute SEER Pediatric Monograph INTERNATIONAL CLASSIFICATION OF CHILDHOOD CANCER (ICCC) Source: Kramárová E, Stiller CA, Ferlay J, Parkin DM, Draper GJ, Michaelis J, Neglia J, Qureshi S (1996) International Classification of Childhood Cancer1996. IARC Technical Report No.29, International Agency for Research of Cancer , Lyon. ICCC GROUP MORPHOLOGY TOPOGRAPHY I Leukemia (a) Lymphoid Leukemia Excluding ALL 9820, 9822-9827, 9850 C00.0-C80.9 ALL 9821 C00.0-C80.9 (b) Acute Leukemia Excluding AML 9840, 9841, 9864, 9866, 9867, 9891, 9894, 9910 C00.0-C80.9 AML 9861 C00.0-C80.9 (c) Chronic Myeloid Leukemia 9863, 9868 C00.0-C80.9 (d) Other Specified Leukemias 9830, 9842, 9860, 9862, 9870-9890, 9892, 9893, 9900, 9930-9941 C00.0-C80.9 (e) Unspecified ...

XIII 157 National Cancer Institute SEER Pediatric Monograph CANCER AMONG ADOLESCENTS 15-19 YEARS OLD HIGHLIGHTS Incidence ? The incidence of cancer among adolescents (i.e., 15-19 year-olds) in SEER areas for 1986-95 was 202.2 per million, which was similar to the incidence of cancer among 0-4 year-olds and substantially greater than the incidence for 5-9 and 10-14 year- olds (Table XIII.1). ? The spectrum of cancers that occurred among 15-19 year-olds was distinctive from those that occurred in young children. For SEER areas from 1986-95, the most common tumors among adolescents were Hodgkin’s disease (16.1%), germ cell tumors (15.2%), CNS tumors (10.0%), non-Hodgkin’s lymphoma (NHL) (7.6%), thyroid cancer (7.2%), malignant melanoma (7.0%), and acute lymphoblastic leuke- mia (ALL) (6.4%) (Figure XIII.1 and Table XIII.1). ? ...

175 Burden of Suffering The term “oral cancer ” includes a diverse group of tumors arising from the oral cavity. Usually included are cancers of the lip, tongue, pharynx, and oral cavity. The annual incidence of oral cancer in the U.S. is about 11/100,000 population, with a male/female ratio greater than 2:1. 1 Oral cancer is responsible for 2% of all cancer deaths in the U.S., and it is pro- jected to account for over 28,000 new cases and about 8,400 deaths in 1995. 2 Fifty-three percent of oral cancers have spread to regional or distant structures at the time of diagnosis. 1 Overall 5-year survival is 52%, but it ranges from 79% for localized disease to 19% if distant metastases are pre- sent. 1 The natural history of each type of cancer can be quite different. Cancer of the lip accounts for 11% of new cases of oral cancer ...

SUPPLEMENTAL CANCER / INTENSIVE CARE INSURANCE 2006 ENROLLMENT FORM (Please Print) Select your Enrollment Type: New Hire Open Enrollment Qualifying Status Change 0 0 Name: Agency Name: Complete Mailing Address: Work Phone: ( ) Home Phone: ( ) Add Drop Cancer /Intensive Care 8/16/05 Plan Code You may: ADD eligible dependents not currently covered and/or DROP ineligible dependents. $24.40 $41.70 $34.50 $36.50 $44.70 Plan Code $46.20 Plan Code Plan Code * RELATIONSHIP: Put the number that is next to the relationship, an example is Spouse-1 then you would put the 1 in the "Rel. column below. Spouse - 1, Child - 2, Legal Guardianship - 3, Grandchild - 4, Legally Adopted Child - 5, Foster Child - 6, Step Child -7, Unborn Child - 8 $18.18 $34.40 $33.50 $40.20 ...

PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATIONP ATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATIONP ATIENT INFORMATION PATIENT PATIENT INFORMATION Prostate cancer A collectable guide for you to use with your patients What is prostate cancer ? The prostate is a gland about the size of a chestnut. It lies at the base of the bladder, wrapped around the urethra – the tube that carries urine from the bladder out of the body (see above). The healthy prostate produces fluid ...

Ovarian Cancer Product Guide Provided by Page 2 If you are diagnosed with ovarian cancer , you are not alone. More than 22,000 women are diagnosed with ovarian cancer each year. To ease the burden of this diagnosis on each and every woman, the Gynecologic Cancer Foundation has collected information about various ovarian cancer organizations, and created this guide as a simple and concise resource of available support. A network of support. Where there’s knowledge, there’s hope Inside the guide, you will find a list of national organizations that provides information and products related to ovarian cancer . Please select the materials you would like to receive, place a postage stamp on each card, and mail it to the specific organization. Within three weeks, you should receive the requested information from that organization. For additional ...

Environmental and Occupational Causes of Cancer A Review of Recent Scientific Literature Richard Clapp, D.Sc. Genevieve Howe, MPH Molly Jacobs Lefevre, MPH Prepared by Boston University School of Public Health and the Environmental Health Initiative, University of Massachusetts Lowell For the Cancer Working Group of the Collaborative on Health and the Environment September 2005 A Publication of the Lowell Center for Sustainable Production University of Massachusetts Lowell Page 2 Acknowledgements The authors gratefully acknowledge the following organizations and individuals for their contributions to this paper: o The Cancer Working Group of the Collaborative on Health and the Environment for initiating this project. o The Mitchell Kapor Foundation for the ...

University of Virginia Cancer Center Transforming the Landscape of Health Care Page 2 Today we approach a historic moment in cancer care. Forty years of intensive cancer research are about to pay off. Powerful new treatments and technologies may soon give us the ability not only to diagnose and treat cancer , but to control and prevent it. The landscape of cancer care is about to change dramatically—but there is still much we must do. Realizing the promise of this new generation of cancer care will require bold new models of treatment, research, and outreach. At the UVa Cancer Center, we have laid a strong foundation for this future. We have pioneered a multispecialty, patient-centered, collaborative model for clinical care. We have attracted researchers in key areas critical to our basic understanding of cancer . Our renowned scientists are leading the way in developing ...

a GAO United States General Accounting Office Report to Congressional Committees September 2003 BREAST CANCER RESEARCH STAMP Effective Fund-Raiser, but Better Reporting and Cost-Recovery Criteria Needed GAO-03-1021 Page 2 Although the U.S. Postal Service (the Service) has not tracked or estimated all costs associated with the BCRS program, it reported that the bulk of BCRS costs, from inception through May 16, 2003, were about $9.5 million. In April 2000, GAO recommended that the Service issue BCRS cost-recovery regulations and make available cost data and analyses to provide postal ratepayers assurance they were not involuntarily subsidizing BCRS costs. The Service issued regulations in July 2000, but it has not yet submitted the recommended data and analyses to Congress. Service officials attributed the ...

Cervical Cancer Screening and Prevention Centers for Disease Control & Prevention (CDC) National Center for HIV, STD, & TB Prevention Division of STD Prevention Modified from an original product developed by the Gynecologic Cancer Foundation (GCF), with the support of the National Cervical Cancer Coalition (NCCC) Page 2 About This Presentation ? In this presentation, you will learn about old and new methods of cervical cancer screening ? We hope that this presentation will help women to take an active part in their health ? It does not replace a doctor’s diagnosis or treatment Page 3 Cervical Cancer Screening and Prevention ? You can prevent cervical cancer with screening. ? Screening is the search ...

SEER Cancer Statistics Review 1975-2002 National Cancer Institute Cancer Facts & Figures – 2005, American Cancer Society (ACS), Atlanta, Georgia, 2005. Excludes basal and squamous cell skin and in situ carcinomas except urinary bladder. Incidence projections are based on rates from the NCI SEER Program 1979-2001. a Estimated deaths for colon & rectum cancers are combined. b Carcinoma in situ of the breast accounts for about 58,490 new cases annually, and melanoma in situ accounts for about 46,170 new cases annually. c More deaths than cases suggests lack of specificity in recording underlying causes of death on death certificate. Estimated New Cases Estimated Deaths Primary Site Total Males Females Total Males Females All Sites 1,372,910 710,040 662,870 570,280 295,280 275,000 Oral ...

SEER Cancer Statistics Review 1975-2002 National Cancer Institute Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). a SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). b NCHS public use data file for the total US. c SEER 9 areas. d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality. - Statistic could not be calculated due to less than 25 cases in the time interval. Incidence a US Mortality b Survival c (1998-2002) (1998-2002) (1995-2001) Site Total Males Females Total ...

Get Checked for Colon Cancer 4 1 1 2 2 2 If you’re 50 or older,or at high risk,get a colonoscopy to prevent colon cancer . Other Colon Cancer Tests There are other colon cancer tests, which, while not as effective as colonoscopy, are much better than no test at all. A positive result on any of these tests should be followed up with colonoscopy. Fecal Occult Blood Test (FOBT) • FOBT is an acceptable alternative to colonoscopy for people who are not at high risk for colon cancer . • It finds small amounts of hidden (occult) blood in stool. • FOBT includes instructions on taking stool samples at home and returning them for testing. Sigmoidoscopy • Is similar to colonoscopy, but with several differences. • Sigmoidoscopy examines less than half of the colon (not the entire colon, as colonoscopy does). • It doesn’t ...

National Cancer Institute SEER Program 128 CANCER CONTROL IN MINORITY AND UNDERSERVED POPULATIONS C ancer affects various population subgroups in the United States in distinct ways. The statistics in this monograph show that black men have the highest incidence rate of cancer , due to excesses of prostate and lung and bronchus cancers , while American Indian men in New Mexico have the lowest rate. Among women, non-Hispanic white women have the highest incidence rate, due mainly to their excess of breast cancer , while American Indian women in New Mexico and Korean women have the lowest rates. Interestingly, the five most commonly diagnosed cancers among men in every racial/ethnic group include lung and bronchus, prostate and colorectal cancers . Oral cancers , however, are among the five most frequently ...

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 U.S. standard population by 5-year age groups using the Joinpoint Regression Program. a Trends are from the SEER 9 areas. b Trends are from the NCHS public use data file. ’ The APC is significantly different from zero (p<.05). Table IV-1 FEMALE BREAST CANCER (Invasive) TRENDS IN SEER INCIDENCE a AND U.S. MORTALITY b USING THE JOINPOINT REGRESSION PROGRAM, 1973-1999 WITH UP TO THREE JOINPOINTS BY RACE AND AGE All Races Whites Blacks Year APC Year APC Year APC SEER Cancer Incidence a Age - All Ages 1973-80 -0.6 1973-80 -0.5 1973-79 -0.7 1980-87 3.7 ’ 1980-87 3.8 ’ 1979-86 3.9 ’ 1987-99 0.5 ’ 1987-99 0.4 1986-99 0.9 ’ ...

SEER Cancer Statistics Review 1975-2002 National Cancer Institute Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute. ( h ttp://srab. cancer .gov/joinpoint/ ). The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). a Trends are from the SEER 9 areas. b Trends are from the NCHS public use data file for the total US. c The APC is significantly different from zero (p<.05). Joinpoint Segment 1 Joinpoint Segment 2 Joinpoint Segment 3 Joinpoint Segment 4 Year APC Year APC Year APC Year APC SEER Cancer Incidence a All Races Male and Female 1975-1977 6.1 1977-1980 -6.4 1980-1996 2.3 c 1996-2002 5.6 c All Races Male 1975-1977 5.6 ...

SEER Cancer Statistics Review 1975-2002 National Cancer Institute Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute. ( h ttp://srab. cancer .gov/joinpoint/ ). The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). a Trends are from the SEER 9 areas. b Trends are from the NCHS public use data file for the total US. c The APC is significantly different from zero (p<.05). Joinpoint Segment 1 Joinpoint Segment 2 Joinpoint Segment 3 Joinpoint Segment 4 Year APC Year APC Year APC Year APC SEER Cancer Incidence a All Races Male and Female 1975-1990 3.6 c 1990-1995 1.5 c 1995-2002 -0.3 All Races Male 1975-1991 4.3 c 1991-2002 ...

SEER Cancer Statistics Review 1975-2002 National Cancer Institute Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute. ( h ttp://srab. cancer .gov/joinpoint/ ). The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). a Trends are from the SEER 9 areas. b Trends are from the NCHS public use data file for the total US. c The APC is significantly different from zero (p<.05). Joinpoint Segment 1 Joinpoint Segment 2 Joinpoint Segment 3 Joinpoint Segment 4 Year APC Year APC Year APC Year APC SEER Cancer Incidence a All Races Male and Female 1975-1988 0.1 1988-2002 -2.6 c All Races Male 1975-1988 -0.2 1988-2002 -2.8 c All Races Female ...

SEER Cancer Statistics Review 1975-2002 National Cancer Institute Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute. ( h ttp://srab. cancer .gov/joinpoint/ ). The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). a Trends are from the SEER 9 areas. b Trends are from the NCHS public use data file for the total US. c The APC is significantly different from zero (p<.05). Joinpoint Segment 1 Joinpoint Segment 2 Joinpoint Segment 3 Joinpoint Segment 4 Year APC Year APC Year APC Year APC SEER Cancer Incidence a All Races Male and Female 1975-1992 1.2 c 1992-2002 -0.3 All Races Male 1975-2002 0.7 c All Races Female 1975-1997 0.9 ...